Peritoneal Dialysis Fluid Polyphenolic Biocompatibility

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current peritoneal dialysis fluids cause cytotoxicity due to high glucose concentrations, glucose degradation products, low pH, and supra-physiologic lactate concentrations, leading to inflammatory reactions and fibrosis, which decreases the efficacy and longevity of dialysis treatment.

Innovation Solution

A peritoneal therapeutic fluid containing biocompatibility enhancing agents such as polyphenolic compounds like Resveratrol and Piceid, which reduce cytotoxicity to human peritoneal mesothelial cells, thereby increasing cell viability and reducing fibrosis.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Stress or pressure

If high glucose concentration is used to establish osmotic pressure in peritoneal dialysis fluid, then osmotic pressure is achieved, but cytotoxicity increases and cell viability decreases

Engineering Contradiction:

Improveosmotic pressureVSAvoidcytotoxicity

Core Design Contradiction:

Stress or pressureVSObject-affected harmful factors

Solution Approach 1:

The patent introduces a biocompatibility enhancing agent as an intermediary substance that mediates between the osmotic pressure requirement and cell viability protection. This agent absorbs the harmful effects of high glucose concentration while allowing the osmotic pressure function to remain effective.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the chemical composition parameters of the dialysis fluid by adding biocompatibility enhancing agents with specific properties (scavenging radicals, chelating metals, anti-inflammatory activity) to modify the overall effect of the high glucose concentration from cytotoxic to biocompatible.

Inventive Principle:

Principle #35Parameter changes

2Stress or pressure

If glucose degradation products are present in peritoneal dialysis fluid, then osmotic pressure is maintained, but inflammatory reactions and fibrosis increase

Engineering Contradiction:

Improveosmotic pressureVSAvoidinflammatory reactions

Core Design Contradiction:

Stress or pressureVSObject-generated harmful factors

Solution Approach 1:

The patent converts the harmful glucose degradation products into beneficial components by adding biocompatibility enhancing agents that actively scavenge radicals and chelate metals, transforming the cytotoxic environment into a protective one that reduces inflammation and fibrosis.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

3Loss of substance

If low pH is used to reduce glucose degradation product formation, then GDP formation is reduced, but cytotoxicity increases

Engineering Contradiction:

Improveglucose degradation product formationVSAvoidcytotoxicity

Core Design Contradiction:

Loss of substanceVSObject-affected harmful factors

Solution Approach 1:

The patent introduces biocompatibility enhancing agents as intermediary substances that protect cells from the low pH environment while allowing the pH control strategy to continue reducing glucose degradation product formation.

Inventive Principle:

Principle #24Intermediary (Mediator)

4Stability of the object's composition

If supra-physiologic concentrations of lactate buffer are used, then pH buffering is achieved, but cytotoxicity and fibrosis increase

Engineering Contradiction:

ImprovepH bufferingVSAvoidcytotoxicity

Core Design Contradiction:

Stability of the object's compositionVSObject-affected harmful factors

Solution Approach 1:

The patent changes the composition parameters by adding biocompatibility enhancing agents that modify the overall biological effect of the high lactate concentration, transforming it from cytotoxic to biocompatible while maintaining pH buffering stability.

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The use of polyphenolic compounds like Resveratrol and Piceid in peritoneal dialysis fluids decreases cytotoxicity, enhances cell viability, and reduces fibrosis, thereby improving the long-term efficacy and duration of peritoneal dialysis treatment.

Implementation Method 1

the patient's highly capilarized peritoneum in the abdomen as a membrane across which fluids and dissolved substances (electrolytes, urea, glucose and other small molecules) are exchanged from the blood

Methodology Applied

Scientific EffectOsmosis: Osmosis

Implementation Method 2

fluids and dissolved substances (electrolytes, urea, glucose and other small molecules) are exchanged from the blood

Methodology Applied

Scientific EffectDiffusion: Diffusion

Data Source

PatentUS11160766B2Peritoneal therapeutic fluid

Publication Date: 2021.11.02 OPTERION HEALTH AG

AI summary

Peritoneal therapeutic fluid comprising one or more of a biocompatibility enhancing agent (BCA) that is selected from the group consisting of a polyphenolic compound, a metabolite of a polyphenolic compound which is obtained by metabolization in the human or animal body, a salt or a glycoside of a polyphenolic compound.